Gedeon Richter announces availability of oral contraception Drovelis
Option contains new, synthetic version of naturally occurring oestrogen
Read Moreby John Pinching | Oct 20, 2022 | News | 0
Option contains new, synthetic version of naturally occurring oestrogen
Read Moreby John Pinching | May 13, 2022 | News | 0
The therapy offers patients a convenient alternative to surgery or injections and can be administered at home
Read Moreby Iona Everson | Dec 8, 2021 | News | 0
The Evra hormonal patch can be worn discreetly and according to Gedeon Richter UK Ltd, is over 99% effective at pregnancy prevention
Read Moreby Selina McKee | Dec 7, 2020 | News | 0
The drug is administered intravaginally as a local oestrogen therapy for treatment of vaginal atrophy due to oestrogen deficiency.
Read Moreby Selina McKee | Apr 15, 2020 | News | 0
Lenzetto, an estradiol spray, has been shown to reduce frequency and severity of hot flushes in post-menopausal women
Read Moreby Selina McKee | Mar 7, 2018 | News | 0
European regulators have accepted a resubmission of Gedeon Richter’s biosimilar to Amgen’s Neulasta.
Read Moreby Selina McKee | Dec 19, 2017 | News | 0
A late-stage study assessing Allergan/Gedeon Richter’s cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder has hit its primary target.
Read Moreby Selina McKee | Jul 19, 2017 | News | 0
European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia.
Read Moreby Selina McKee | Jan 18, 2017 | News | 0
Allergan and Gedeon Richter are gearing up to file ulipristal acetate in the US in the second half of this year, in the hope of securing approval for the first oral treatment option for women suffering from uterine fibroids in the country.
Read Moreby Selina McKee | Aug 26, 2016 | News | 0
Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the National Health Service for the first time, after cost regulators endorsed Gedeon Richter’s once-daily pill Esmya as an option.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
